Anti-CD20-Mediated B Cell Depletion Is Associated With Bone Preservation in Lymphoma Patients and Bone Mass Increase in Mice

Immunotherapy with anti-CD20-specific antibodies (rituximab), has become the standard of care for B cell lymphoproliferative disorders and many autoimmune diseases. In rheumatological patients the effect of rituximab on bone mass yielded conflicting results, while in lymphoma patients it has not yet...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Front Immunol
Päätekijät: Kolomansky, Albert, Kaye, Irit, Ben-Califa, Nathalie, Gorodov, Anton, Awida, Zamzam, Sadovnic, Ofer, Ibrahim, Maria, Liron, Tamar, Hiram-Bab, Sahar, Oster, Howard S., Sarid, Nadav, Perry, Chava, Gabet, Yankel, Mittelman, Moshe, Neumann, Drorit
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Frontiers Media S.A. 2020
Aiheet:
Immunology
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7604358/
https://ncbi.nlm.nih.gov/pubmed/33193330
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2020.561294
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia